Investor Braeden Lichti discloses 5.05% enVVeno (NVNO) ownership stake

Rhea-AI Filing Summary

Braeden Lichti and Northstrive Fund II LP have disclosed significant ownership stakes in enVVeno Medical Corp. Lichti reports beneficial ownership of 33,151 shares of common stock, representing 5.05% of the company, while Northstrive Fund II LP reports 20,129 shares, or 3.07%.

The percentages are based on 655,606 shares of enVVeno Medical Corp common stock issued and outstanding as of January 20, 2026, as reported by the company. Lichti, a Canadian citizen, is the manager of Northstrive Fund II LP, a Delaware entity, and holds both sole and shared voting and dispositive power over different portions of the shares.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

enVVeno Medical Corp

(Name of Issuer)

Common Stock, $0.00001 par value per share

(Title of Class of Securities)

29415J205

(CUSIP Number)

02/10/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 29415J205

1

Names of Reporting Persons

Northstrive Fund II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 20,129.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 20,129.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

20,129.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.07 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Braeden Lichti is, as of the date of this Schedule 13G, the Manager of Northstrive Fund II LP. Percentage ownership is calculated based on 20,129 shares beneficially owned by Northstrive Fund II LP, out of 655,606 shares of enVVeno Medical Corporation ("Issuer")'s issued and outstanding shares of common stock, par value $0.00001 per share ("Common Stock") on January 20, 2026, as reported on the Issuer's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission ("Commission") on January 20, 2026.

SCHEDULE 13G

CUSIP No. 29415J205

1

Names of Reporting Persons

Braeden Lichti

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 13,022.00
6	Shared Voting Power 20,129.00
7	Sole Dispositive Power 13,022.00
8	Shared Dispositive Power 20,129.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

33,151.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.05 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Braeden Lichti is, as of the date of this Schedule 13G, the Manager of Northstrive Fund II LP. Percentage ownership is calculated based on 33,151 shares of enVVeno Medical Corporation ("Issuer") beneficially owned by Mr. Lichti, out of 655,606 shares of the Issuer's issued and outstanding shares of Common Stock on January 20, 2026, as reported on the Issuer's Current Report on Form 8-K filed with the Commission on January 20, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: enVVeno Medical Corp
(b)	Address of issuer's principal executive offices: 70 Doppler Irvine, CA 92618
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Northstrive Fund II LP; and (ii) Braeden Lichti ("Mr. Lichti"). The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
(b)	Address or principal business office or, if none, residence: 120 Newport Center Drive, Suite 250 Newport Beach, CA 92660
(c)	Citizenship: Northstrive Fund II LP is a Delaware corporation. Mr. Lichti is a citizen of Canada.
(d)	Title of class of securities: Common Stock, $0.00001 par value per share
(e)	CUSIP No.: 29415J205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Rows 5-11 of the cover page for each Reporting Person and is incorporated herein by reference for each Reporting Person.
(b)	Percent of class: Braeden Lichti: 5.05% Northstrive Fund II LP: 3.07%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Northstrive Fund II LP: 0 Braeden Lichti: 13,022
	(ii) Shared power to vote or to direct the vote: Northstrive Fund II LP: 20,129 Braeden Lichti: 20,129
	(iii) Sole power to dispose or to direct the disposition of: Northstrive Fund II LP: 0 Braeden Lichti: 13,022
	(iv) Shared power to dispose or to direct the disposition of: Northstrive Fund II LP: 20,129 Braeden Lichti: 20,129
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Northstrive Fund II LP

Signature:	/s/ Braeden Lichti
Name/Title:	Braeden Lichti, Manager
Date:	02/10/2026

Braeden Lichti

Signature:	/s/ Braeden Lichti
Name/Title:	Braeden Lichti
Date:	02/10/2026

FAQ

What ownership stake in enVVeno Medical Corp (NVNO) does Braeden Lichti report?

Braeden Lichti reports beneficial ownership of 33,151 enVVeno shares, or 5.05% of the company. This percentage is calculated against 655,606 common shares outstanding as of January 20, 2026, as disclosed in enVVeno’s current report on Form 8-K.

How many enVVeno Medical Corp (NVNO) shares does Northstrive Fund II LP own?

Northstrive Fund II LP reports beneficial ownership of 20,129 enVVeno common shares, equal to 3.07% of the company. The stake is calculated based on 655,606 shares outstanding and reflects shared voting and dispositive power over all 20,129 shares.

How is the 5.05% ownership of enVVeno (NVNO) by Braeden Lichti structured?

Lichti’s 5.05% beneficial stake includes 13,022 shares with sole voting and dispositive power and 20,129 shares with shared power. The shared portion aligns with the position of Northstrive Fund II LP, where Lichti serves as manager as of the statement date.

What share count did enVVeno Medical Corp (NVNO) report as outstanding for this Schedule 13G?

The ownership percentages use 655,606 enVVeno common shares issued and outstanding as of January 20, 2026. This figure comes from the company’s Form 8-K, and both Lichti’s 5.05% and Northstrive Fund II LP’s 3.07% are calculated against this baseline.

Who are the reporting persons on this enVVeno Medical Corp (NVNO) Schedule 13G?

The Schedule 13G is jointly filed by Northstrive Fund II LP and Braeden Lichti. Northstrive is a Delaware entity, while Lichti is a Canadian citizen and serves as manager of Northstrive Fund II LP, giving him beneficial ownership over both direct and shared holdings.

What voting and dispositive powers do the enVVeno (NVNO) reporting holders have?

Northstrive Fund II LP has shared voting and dispositive power over 20,129 shares and no sole power. Braeden Lichti has sole voting and dispositive power over 13,022 shares and shared power over 20,129 shares, matching the fund’s reported position.